Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Edgewise Therapeutics, Inc. - Common Stock (NQ:EWTX)

14.58 -0.12 (-0.82%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Edgewise Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments... 
Via Benzinga
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
From Edgewise Therapeutics
Via Business Wire
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
Edgewise Therapeutics to Participate at SVB Leerink 11th Annual Global Healthcare Conference on February 16
From Edgewise Therapeutics
Via Business Wire
52 Biggest Movers From Friday
Gainers Knightscope, Inc. (NASDAQ: KSCP) surged 175.6% to close at $3.40 on Friday. The company, on Thursday, priced its IPO at $10 per share. Imperial Petroleum Inc. (NASDAQ:... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Provention Bio (NASDAQ:PRVB) stoc... 
Via Benzinga
Stocks Move Higher Midday, Still Pacing for Weekly Losses
Stocks are continuing their rollercoaster pattern midday, as Wall Street attempts to lift itself out of the worst selloff since March 2020. 
Via Talk Markets
33 Stocks Moving In Friday's Mid-Day Session
Gainers Imperial Petroleum Inc. (NASDAQ: IMPP) shares jumped 126% to $2.6219. Imperial Petroleum, last month, posted Q3 revenue of $4.1 million. Yoshitsu Co., Ltd (NASDAQ: TKLF... 
Via Benzinga
50 Biggest Movers From Yesterday
Gainers Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) shares surged 63.7% to settle at $2.21 on Wednesday after the company announced that in preclinical studies its lead... 
Via Benzinga
Mid-Afternoon Market Update: Nasdaq Down 300 Points; Annexon Shares Plunge
Toward the end of trading Wednesday, the Dow traded up 0.24% to 36,711.36 while the NASDAQ fell 1.93% to 15,321.38. The S&P also fell, dropping 0.80% to 4,755.18. The U.S. has... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Lixte Biotech Holdings (NASDAQ:LIXT) stock increased by 70.4% to $2.3 during Wednesday's regular session. Trading volume for this security as of 12:31 EST is... 
Via Benzinga
34 Stocks Moving In Wednesday's Mid-Day Session
Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares climbed 49.7% to $15.45 after the company announced it acquired exclusive rights to novel mRNA biomarkers. Data Storage... 
Via Benzinga
Edgewise Therapeutics Shares Jump After Positive Data On Becker Muscular Dystrophy Study
Edgewise Therapeutics Inc (NASDAQ: EWTX) posted positive topline results from Phase 1b trial of EDG-5506, designed to protect injury-susceptible fast skeletal... 
Via Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech Partner For Shingles Vaccine, Annexon Huntington Disease Study Disappoints, Amneal Buys Neurology Assets
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Annexon Announces Mixed Phase 2 Data From Huntington Disease Trial Annexon,... 
Via Benzinga
Edgewise Therapeutics Announces Positive Topline Results From the EDG-5506 Phase 1b Clinical Trial in Adults With Becker Muscular Dystrophy (BMD)
From Edgewise Therapeutics
Via Business Wire
The Week Ahead In Biotech (Jan. 2-Jan. 8): Stray Clinical Readouts In Focus In Slow News Week
Biotech stocks came under selling pressure in the final week of 2021, although they carved out modest gains for the year. Here are the key catalysts that can sway biotech stocks in the unfolding week. 
Via Talk Markets
The Week Ahead In Biotech (Jan 2-Jan. 8): Stray Clinical Readouts In Focus In Slow News Week
Biotech stocks came under selling pressure in the final week of 2021, although they carved out modest gains for the year. On the regulatory front, the Food And Drug Administration... 
Via Benzinga
Edgewise Therapeutics to Report Phase 1b Topline Results of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD) on January 5, 2022, and Initiates ARCH Follow-On Open Label BMD Study
From Edgewise Therapeutics
Via Business Wire
63 Biggest Movers From Friday
Gainers Spruce Biosciences, Inc. (NASDAQ: SPRB) jumped 102.8% to close at $5.03 on Friday after Oppenheimer initiated coverage on the stock with an Outperform rating and a $15... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Adicet Bio (NASDAQ:ACET) shares i... 
Via Benzinga
60 Biggest Movers From Yesterday
Gainers Insignia Systems, Inc. (NASDAQ: ISIG) shares jumped 200.4% to close at $15.05 on Monday after the company announced the commencement of a formal process to explore... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Celyad Oncology (NASDAQ:CYAD) stock moved upwards by 32.58% to $4.72 during Friday's regular session. Trading volume for this security as of 12:30 EST is 45.2... 
Via Benzinga
Edgewise Therapeutics to Participate at Evercore ISI 4th Annual HEALTHCONx Conference on December 2
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics Reports Third Quarter 2021 Financial Results
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics Posts Data From Early-Stage Muscle Wasting Disease Trial
Edgewise Therapeutics Inc (NASDAQ: EWTX) has announced topline results from the MAD portion of Phase 1 trial of EDG-5506, designed to protect skeletal muscle... 
Via Benzinga
Edgewise Therapeutics Announces Positive Topline Results from the EDG-5506 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers (HVs) and Doses First Becker Muscular Dystrophy (BMD) Patients
From Edgewise Therapeutics
Via Business Wire
Chief Scientific Officer Of Edgewise Therapeutics Sold $1.07 Million In Stock
Russell Alan J, Chief Scientific Officer at Edgewise Therapeutics (NASDAQ:EWTX), made a large insider sell on September 27, according to a new SEC filing. What Happened: A Form 4... 
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
Edgewise Therapeutics to Participate at SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines 1x1 Event on September 23
From Edgewise Therapeutics
Via Business Wire
The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN)... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 19) Alkermes plc (NASDAQ: ALKS... 
Via Benzinga
Exposures COVID-19
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS